Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-07-0843
European Journal of Endocrinology, Vol 158, Issue 5, 705-709
Copyright © 2008 by Society of the European Journal of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by F. Magitta, N.
Right arrow Articles by Husebye, E. S
PubMed
Right arrow PubMed Citation
Right arrow Articles by F. Magitta, N.
Right arrow Articles by Husebye, E. S

CLINICAL STUDIES

Autoimmune polyendocrine syndrome type I in Slovakia: relevance of screening patients with autoimmune Addison's disease

Ng'weina F. Magitta1,4,7, Mikulás Pura2, Anette S Bøe Wolff3,6, Peter Vanuga2, Anthony Meager5, Per M Knappskog1,7 and Eystein S Husebye3,6

1 Institute for Clinical Medicine, University of Bergen, N-5021 Bergen, Norway2 Department of Endocrinology, National Institute of Endocrinology and Diabetology, 034 91 Lubochna, Slovakia3 Section of Endocrinology, Institute of Medicine, University of Bergen, N-5021 Bergen, Norway4 Department of Biochemistry, Muhimbili National Hospital, Muhimbili University of Health and Allied Sciences, PO Box 65001 Dar es Salaam, Tanzania5 The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Herts EN6 3QG, UK6 Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway7 Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, N-5021 Bergen, Norway

(Correspondence should be addressed to E S Husebye; Email: eystein.husebye{at}helse-bergen.no)

Background: Autoimmune polyendocrine syndrome type I (APS I) is a monogenic disease affecting endocrine glands and other organs due to mutations of the autoimmune regulator (AIRE) gene. There is a wide variability in clinical phenotypes in patients with APS I, which makes the diagnosis a challenge.

Objective: To screen for APS I among Slovakian patients with sporadic Addison's disease and clinical features that raised the suspicion of APS I.

Methods: All 14 exons and exon–intron boundaries of the AIRE gene were sequenced. In addition, autoantibodies specific for Addison's disease and polyendocrine syndromes were assayed.

Results: Using clinical criteria we identified four patients with APS I in three families. Two patients had a novel missense mutation in exon 2 (c.274C>T, p.R92W) and either the Finnish major mutation (c.769C>T) or the common 13 bp deletion (c.967–979del13bp). APS I was diagnosed in a brother of the latter after his death due to an adrenal crisis. A fourth patient had primary adrenal failure and hypoparathyroidism without AIRE mutations or APS-I specific autoantibodies.

Conclusions: Four patients with APS I were found in a Slovakian cohort of Addison patients, although the lack of detectable AIRE mutations and APS I-specific autoantibodies raises uncertainty regarding the pathogenesis in one of the patients. This study demonstrates the merits of screening patients with phenotypic features or autoantibody findings that could indicate APS I, even in adult patients. It is necessary to identify APS I patients in order to provide appropriate treatment and follow-up of the various components of APS I.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of the European Journal of Endocrinology.